Related Experiment Video

Updated: Jul 13, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1)

Chun-Te Chiang1, Tzong-Der Way, Jen-Kun Lin

  • 1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, No. 1, Section 1, Jen-ai Road, Taipei 10018, Taiwan.

Molecular Cancer Therapeutics
|July 11, 2007
PubMed

Insights

Luteolin promotes HER2 degradation, inhibiting cancer cell growth. Combining luteolin with mTOR inhibitors, like rapamycin, enhances apoptosis by suppressing p21, offering a promising strategy for HER2-overexpressing tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2 overexpression is linked to poor prognosis and therapeutic resistance in cancers.
  • Luteolin, a natural flavonoid, shows potential in cancer treatment.
  • The Akt/mammalian target of rapamycin (mTOR) pathway is crucial in cancer cell survival.

Purpose of the Study:

  • To investigate luteolin's effect on HER2 degradation and its therapeutic potential in HER2-overexpressing cancers.
  • To explore the role of p21 and Akt/mTOR signaling in luteolin's mechanism of action.
  • To evaluate the efficacy of combining luteolin with mTOR inhibitors.

Main Methods:

  • In vitro studies on HER2-overexpressing cancer cells to assess luteolin's impact on cell proliferation, apoptosis, and signaling pathways (HER2, Akt/mTOR, p21).
  • In vivo studies using nude mice with xenografted tumors to evaluate luteolin and rapamycin efficacy.
  • Manipulation of p21 expression using small interfering RNA (siRNA).

Main Results:

  • Luteolin effectively stimulates HER2 degradation, inhibits proliferation, and induces apoptosis in HER2-overexpressing cancer cells.
  • Low doses of luteolin up-regulated p21, while high doses down-regulated it; transient Akt/mTOR inhibition was observed.
  • Combination therapy with luteolin and rapamycin (an mTOR inhibitor) enhanced apoptosis and suppressed p21, showing significant tumor growth inhibition in vivo.

Conclusions:

  • Luteolin is a potent stimulator of HER2 degradation with therapeutic potential against HER2-overexpressing cancers.
  • Suppression of p21 expression, potentially through combination with mTOR inhibitors, enhances luteolin's efficacy.
  • Combination of luteolin with mTOR inhibitors represents a promising strategy for treating HER2-overexpressing tumors.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...